Germany's new ZB MED law is intended to ensure that a single fragile pipeline does not jeopardise good science. Experts write that this law brings competition to PubMed from Germany. Competition, they say, is a very good thing. The law is linked to the institution of ZB MED. The aim is to protect scientific research from the risks of a single database. The article is in the form of an opinion.